ImmBio's lead universal vaccine is against pneumococcal disease, PnuBioVax™, that is in full clinical development with the completion of a Phase I trial.

CAMBRIDGE, UNITED KINGDOM, September 24, 2019 /EINPresswire.com/ -- Following the strategic licensing deal with CNBG, the largest Pharmaceutical Vaccine company in China earlier this year, ImmunoBiology Ltd (“ImmBio”;Immbio.net) has announced that it is searching for additional strategic partners to develop and commercialise its PnuBioVax™ universal pneumococcal vaccine. AEC Partners, a leading life-sciences advisory firm head quartered in Paris, has been appointed to support this initiative which is at Phase 2 clinical stage of development.

ImmBio owns long lasting IP for development of protein-based vaccines which can potentially target a universal group of strains for disease. This is a unique approach in the field of pneumococcal disease and a clear differentiator from other pharmaceutical companies with vaccine products that target only a small subset of pre-existing Streptococcus pneumoniae polysaccharide variants or serotypes.

Hilde Depraetere, Acting Executive Director at the European Vaccine Initiative (EVI) said: “We are thrilled with our collaboration with ImmBio in the development of the next generation vaccine, PnuBioVax™. The protein-based vaccine has the potential to address the limitations of current serotype dependent vaccines and provide with a long-lasting solution that would impact the socio-economic burden of the disease in both developed and developing countries”.

PnuBioVax™ is a Phase 2-ready protein vaccine, with good Phase 1 clinical safety and immunogenic data, targeting a broad range of Streptococcus pneumoniae serotypes. In pre-clinical studies, PnuBioVax™ was shown to be immunogenic against all S. pneumoniae strains tested to date regardless of the serotype – evidence of a universal vaccine which, together with low cost of manufacture, will give ImmBio market and clinical dominance when PnuBioVax™ is approved by regulatory authorities.

Prof Jeremy Brown, Professor of Respiratory Infection at UCL and an Honorary Consultant at UCLH and a member of the United Kingdom’s Joint Committee on Vaccines and Immunisation, said “Significant pre-clinical data suggests the PnuBioVax™ vaccine can provide serotype-independent protection, thereby potentially addressing the concerns about serotype replacement with the existing capsular polysaccharide vaccines.”

ImmBio’s lead competitor is Pfizer who has reported sales to date of $30 Bn for its polysaccharide-based Prevnar™ vaccine which targets just 13 of more than 90 S. pneumoniae serotypes that have been identified to date. A more serious problem unfolding is the increasing antibiotic resistance (AMR) and emergence of new serotypes not targeted by current vaccines. Pfizer has recently announced the development of a new Prevnar™ polysaccharide-based vaccine targeting as many as 20 serotypes of the pneumococcal bacteria and Merck is positioning its new polysaccharide-based 15-serotype vaccine (V114) as a Prevnar™ competitor.

ImmBio envisions commercialisation partnerships in different regions that will provide, in each geographical area, with a licence to PnuBioVax™ product rights. In addition to these commercial partnerships, Immbio will also seek financial partners to complement the clinical development funding.

Enrique Tabares, CEO of ImmBio, said “We are really excited with the support and the prospects of building a Global Consortium with key strategic and financial partners. Our PnuBioVax™ vaccine has the potential to become the leader in control of pneumonia, a global health problem facing the young and old. We believe that our novel approach to vaccine development can overtake current technologies in development because it offers a universal approach to all pneumococcal strains, both known and those which are likely to develop through mutation and evolution of the bacteria underlying pneumonia. In addition, a universal pneumococcal vaccine would make a significant contribution to the current global efforts to tackle AMR”

For more information about ImmBio, PnuBioVax™, and partnering opportunities for its pipeline drug candidates, please contact:

Jean-Luc Marsat
AEC Partners
Phone: +32 (0)471 90 51 58
Jean-luc.marsat@aec-partners.com

Or

Dr. Enrique Tabares, CEO
Phone: +44 (0)1223 496117
Enrique.Tabares@immbio.com

Or

Dr. Bill Mason, Director
Phone: +44 (0)7785 950134
bill.mason@immbio.com

www.immbio.com

About PnuBioVax
PnuBioVax™ has completed a pre-clinical package and a Phase 1 study demonstrated safety in humans as well as efficient generation of immunity without the use of adjuvants. High anti- PnuBioVax™ titres also correlated with quicker clearance in elderly subjects challenged with pneumococcal bacteria.

About Immunobiology Ltd.
ImmBio is based in Cambridge, UK and is privately funded. ImmBio’s portfolio addresses major unmet healthcare needs in infectious disease.

ImmBio's lead programme is a vaccine against invasive pneumococcal disease, PnuBioVax™, that has recently progressed into full clinical development with the successful completion of a Phase I Clinical trial.

ImmBio was founded based on advances in understanding of the immune system, in particular the key role of the dendritic cell (DC) in the integration of innate and acquired immunity. ImmBio utilises two distinct technology platforms, ImmBioVax™ and ImmunoBodies™ to target antigens to DCs. The lead platform, ImmBioVax, is designed for bacerial vaccines and mimics normal immune responses to a pathogen utilising multi-protein complexes to elicit priming of the immune system.

ImmBio’s unique technologies have the following benefits:
• Induce broad immunity effective against multiple pathogen strains and variants
• Potential universal vaccine technology
• Effective, long-lasting immune responses in diverse human populations
• Emulate normal immune responses to pathogens to optimise the safety profile
• Low cost of goods and a clear regulatory pathway to market

ImmBio’s patent estate covers the products and processes associated with its technologies. The company’s lead ImmBioVax™ programme, PnuBioVax™, targets invasive pneumococcal disease. ImmBio currently have collaborations with many leading research centres, including the co-development of ImmBio's pneumococcal vaccine, PnuBioVax™, with a leading Chinese vaccine organisation, the China National Biotec Group, CNBG.

The company also has other vaccines at early stages of development i.e. for meningitis and tuberculosis, with the potential for a partner to address an even wider range of vaccines.

Bill Mason
Immunobiology Ltd
+44 7785 950134
email us here